This Company Has the Highest Margins and Returns in Indian CDMO.
40% EBITDA margins, 25% ROCE, 14 commercialised molecules with blockbuster end-markets, and fermentation-based peptide capabilities that few peers globally can match The Indian contract research and development manufacturing organisation space has attracted enormous investor attention over the last several years — and for good reason. India’s combination of scientific talent, cost-competitive manufacturing and a … Read more